What it is
Dihexa is a small-molecule compound (not a peptide) developed as a hepatocyte growth factor (HGF)/c-Met pathway activator, studied for synaptogenesis and cognitive-enhancement research. It is sometimes grouped with nootropic peptides in research catalogs, which is why it appears in peptide directories — but its dosing, route, and molecule identity are distinct.
Evidence boundary
Preclinical animal data only; no established human dosing. Research use is limited to laboratory and education contexts.
Trial evidence
- Published animal studies report oral administration improving cognitive performance in models of learning and memory.
Preparation and measurement
Oral dosing — no reconstitution. Available as a powder for laboratory weighing.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Preclinical reference | 2 mg/kg/day | Oral (animal studies) | Once daily | Study-dependent |
Preclinical reference
- Dose
- 2 mg/kg/day
- Draw / measure
- Oral (animal studies)
- Frequency
- Once daily
- Weekly total
- Study-dependent
Weekly totals apply only during the active phase.
Titration rules
- The only published dose reference is preclinical: ~2 mg/kg/day orally in rats for 2–4 weeks (study-dependent).
- There is no established human equivalent — do not scale animal mg/kg directly to human use.
- Not a peptide; if reconstitution math was expected, note that dihexa is used as an oral powder in research.
- Long-term human safety is not characterized.